Who makes GAd20-209-FSP, RP2D?

GAd20-209-FSP, RP2D is developed by Nouscom SRL.

What development phase is GAd20-209-FSP, RP2D in?

GAd20-209-FSP, RP2D is in Phase 1.

Last reviewed 2026-05-14 · How we verify

GAd20-209-FSP, RP2D

Nouscom SRL · Phase 1 active Biologic

At a glance

Generic name	GAd20-209-FSP, RP2D
Sponsor	Nouscom SRL
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GAd20-209-FSP, RP2D CI brief — competitive landscape report
GAd20-209-FSP, RP2D updates RSS · CI watch RSS
Nouscom SRL portfolio CI